Chair: Dr Claire Barton

The Oncology Expert Group covers the development of treatments for all types of cancers—both haematological and solid tumours—including systemic anti-cancer agents, immuno-oncology, targeted radio-isotope therapy, symptomatic support, the application of artificial intelligence algorithms to cancer care, oncology-related devices and diagnostics, and drug-device combinations. This includes exploratory and translational research. The group also considers associated public and clinical issues around cancer, for instance, prevention (for example, in individuals with rare inherited cancer-predisposition syndromes) and screening.

The group also considers patient issues, such as participation in clinical trials, and issues around informed consent of particular relevance to cancer patients e.g. need for/legitimacy of mandatory biopsies, risk-benefit in subjects with very short life expectancy, availability of standard/approved therapies in different geographic regions, and patient support and guidance, including palliative care. Marketing and access to treatments for cancer and the development of regulatory guidelines in oncology also fall under the group’s remit.

Meet some of our members

Some of the group's outputs

Radiopharmaceuticals in the 21st Century

This insightful blog post explores the advancements and challenges in radiopharmaceuticals in the 21st century. It highlights the crucial role of radiopharmaceuticals in various medical applications, including diagnostic imaging and targeted therapy for cancer. The post emphasizes the evolution of techniques and technologies in the production and utilization of radiopharmaceuticals, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Additionally, the blog discusses the regulatory landscape and the need for collaboration among professionals to address emerging issues in the development and use of these radiopharmaceuticals. Overall, the blog provides a comprehensive overview of the current state and prospects of radiopharmaceuticals in modern medicine.

Read the blog.

How to get involved

If you have any suggestions or would like to get involved with an FPM expert group, please let us know

Email fpm@fpm.org.uk